Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 17/20 | 0.52 |
| ▸ | CCND1 | P24385 | 13/20 | 0.52 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | RB1 | P06400 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26341666 | 0.89 | CCNE1 (0.51) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341659 | 0.88 | CCND3 (0.48) | CCND1CDK6CDK4CCND3 | |
| SCHEMBL26341354 | 0.84 | CCNE1 (0.50) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341614 | 0.84 | CCNE1 (0.50) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341638 | 0.84 | CCNE1 (0.50) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26342014 | 0.84 | CCNE1 (0.53) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341426 | 0.84 | CCNE1 (0.53) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341421 | 0.84 | CCNE1 (0.53) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26340872 | 0.83 | CCNE1 (0.49) | CDK2CCNE1CCND1CDK6CCNE2 | |
| SCHEMBL26341387 | 0.83 | CCNE1 (0.49) | CDK2CCNE1CCND1CDK6CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303564-A1 | PYRIMIDINE RING COMPOUND | DPYD, TYMS, TYMP | CDK2 165/4885CCNE1 1815/4885CCND1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.